That CSP article was based upon a report Herzog sent out yesterday. If anyone wants Herzog's report, please send an e-mail request to me at
smokefree@compuserve.com
Below is my take on Herzog's report, which I e-mailed to many e-cig companies and
vaping activists (when I forwarded them Herzog's report).
Herzog is getting bullish on the FDA giving the e-cig industry to Big
Tobacco, but she's spot on in writing
"The key question on e-cigs is how the FDA will deal with pre-market
approvals. In other words, will deeming regulations prevent, limit, or
restrict rapid innovation of the category.Bottom line - if e-cig
innovation is stifled, in our view this could dramatically slow down
conversion from combustible cigs, which would ultimately result in net
negative public health impact"
Unfortunately for the vast majority of e-cig companies and many vapers,
even if FDA changes the 2007 grandfather date in Section 910 to 2013
for e-cigs, e-cig companies would still be required to submit SE
applications (and FDA would have to approve them) for all of the 1,000+
e-cig products in 2014 or 2015 (or shortly after FDA approves the new
regs) in order to keep those products on the US market.
Although the big tobacco companies and some large e-cig companies can
afford spending a half million dollars or more to submit each SE
application, the vast majority of small e-cig companies (including
e-liquid companies) cannot afford to do so, which would sharply reduce
the number of e-cig products on the US market (i.e. from 1,000+
products to no more than several dozen, and probably fewer). Please
note that FDA has only approved about 20 NRT products in the past 30
years.
The only way a small e-cig company could survive is to submit no more
than one or two SE applications for just one or two e-cig products they
think has/have the best chance to generate a return on their
investment. Please note that Altria would only need to submit two SE
applications for their new MarkTen e-cigs (one SE for menthol and one
SE for nonmenthol).
That's why we need to continue exposing and opposing the FDA deeming
regulation.